This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, C. C. Articles by Morton, D. L. Search for Related Content PubMed PubMed Citation Articles by Lee, C. C. Articles by Morton, D. L.

Improved Survival After Lymphadenectomy for Nodal Metastasis From an Unknown Primary Melanoma

Chris C. Lee, Mark B. Faries, Leslie A. Wanek, Donald L. Morton

From the Roy E. Coats Research Laboratories and the Sonya Valley Ghidossi Vaccine Laboratory of the John Wayne Cancer Institute at Saint John's Health Center, Santa Monica, CA

Corresponding author: Donald L. Morton, MD, John Wayne Cancer Institute, 2200 Santa Monica Blvd, Santa Monica, CA 90404; e-mail: mortond{at}jwci.org

Purpose: No primary lesion is identified in 10% to 20% of patients presenting with palpable evidence of regional metastatic melanoma. Because the prognostic significance of unknown primary melanoma (MUP) is unclear, we compared clinical outcomes of patients with MUP and known primary melanoma (MKP) with regional nodal metastases.

Patients and Methods: We reviewed our 13,000-patient prospective melanoma database (1971 through 2005) to identify patients managed with regional lymphadenectomy for palpable nodal metastases from MUP or MKP. Multivariate analysis identified prognostic factors significant for survival. MUP and MKP were then matched by significant covariates. Overall survival (OS) was estimated by Kaplan-Meier method and compared by log-rank analysis.

Results: Multivariate analysis of data from 1,571 study patients identified four significant covariates associated with worse prognosis: age 60 years (hazard ratio [HR] = 1.294; P = .0017), male sex (HR = 1.335; P = .0004), nodal tumor burden one (HR = 1.256; P < .0001), and known primary (HR = 1.507; 95% CI, 1.220 to 1.862; P = .0001). Five-year OS was significantly higher for 262 patients with MUP than for 1,309 patients with MKP (55% ± 6% v 44% ± 3%; P = .0021). Computerized matching of MUP and MKP by four significant covariates (age, sex, nodal tumor burden, and decade of diagnosis) yielded 221 matched pairs. Median and 5-year OS rates were 165 months and 58% ± 7%, respectively, for MUP as compared with 34 months and 40% ± 7%, respectively, for MKP (P = .0006).

Conclusion: Lymphadenectomy is effective for nodal metastasis from MUP. The significantly better postoperative survival for MUP versus MKP suggests a strong endogenous immune response against the primary melanoma. Immunologic studies to identify cell-mediated and antibody components of this response may lead to new approaches for determining melanoma prognosis and treatment.

Supported by Grants No. CA29605 and CA12582 from the National Cancer Institute and by funding from the Wayne and Gladys Valley Foundation (Oakland, CA), the Harold J. McAlister Charitable Foundation (Los Angeles, CA), the Family of Robert Novick (Los Angeles, CA), the Weil Family Fund (Los Angeles, CA), the Wrather Family Foundation (Los Alamos, CA), the Amyx Foundation Inc (Boise, ID), Berton M. Kirshner (Los Angeles, CA), Todd Kirshner (Los Angeles, CA), Mr and Mrs Louis Johnson, (Stanfield, AZ), Heather and Jim Murren (Las Vegas, NV), Mrs Marianne Reis (Lake Forest, CA), and the Wallis Foundation (Los Angeles, CA).

Presented at the 43rd Annual Meeting of the American Society of Clinical Oncology, June 1-5, 2007, Chicago, IL.

Authors’ disclosures of potential conflicts of interest are found at the end of this article.

This article has been cited by other articles:

				J. Matsui, Y. Funahashi, T. Uenaka, T. Watanabe, A. Tsuruoka, and M. Asada Multi-Kinase Inhibitor E7080 Suppresses Lymph Node and Lung Metastases of Human Mammary Breast Tumor MDA-MB-231 via Inhibition of Vascular Endothelial Growth Factor-Receptor (VEGF-R) 2 and VEGF-R3 Kinase Clin. Cancer Res., September 1, 2008; 14(17): 5459 - 5465. [Abstract] [Full Text] [PDF]